27 March 2019

Meningitis is the most deadly manifestation of tuberculosis. Following a series of smaller trials that showed a benefit of high-dose rifampicin for tuberculous meningitis, Reinout van Crevel (Dept of Internal Medicine) and Rob Aarnoutse, Lindsey te Brake and Elin Svensson (Dept of Pharmacy/Pharmacology), theme Infectious diseases and global health, have received funding (4 million British Pounds) from the MRC Wellcome Trust global health trials scheme for a phase 3 randomized clinical trial evaluating high-dose rifampicin in 500 tuberculous meningitis patients in Indonesia, Uganda and South Africa.

Besides intensified antibiotic treatment, targeting damaging inflammation might also improve survival of tuberculous meningitis patients. Following the discovery of a critical role for cerebral tryptophan metabolism (Van Laarhoven et al, Lancet Inf Dis 2018), Van Crevel and colleagues Arjan van Laarhoven, Vinod Kumar and Mihai Netea from the department of Internal Medicine, theme Infectious diseases and global health, have also received 5-year funding (4 million Euro) from the National Institute of Health (NIH, Washington) to apply a ‘multi-omics’ approach in >2000 tuberculous meningitis patients from Vietnam and Indonesia, aiming to find more effective host-directed therapy with collaborators from Boston, Vietnam and Indonesia. 
 

Related news items


Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection

17 February 2021 In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2. read more

Invasive fungal infections in influenza and COVID-19

8 July 2020 The Aspergillus fungus is found in the lungs of many COVID patients. A parallel occurs with influenza patients, who often develop a serious fungal infection. Although such a serious fungal infection seems to occur less frequently in COVID-patients, alertness remains necessary, read more

Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection

29 June 2020 In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2. read more

Study into better protection for healthcare workers against coronavirus infection

19 March 2020 Radboudumc and UMC Utrecht will investigate whether health care workers are better protected against the coronavirus after a vaccination against tuberculosis (BCG vaccine). This vaccine does not directly protect against the coronavirus, but provides a boost to the immune system. read more

15 million Euro to identify new drug targets for HIV

28 February 2019 André van der Ven and Mihai Netea, theme Infectious diseases and global health, and colleagues, will receive 15 million Euro from pharmaceutical company ViiV Healthcare for research into new ways to fight the HIV virus. The aim of the HIV 2000+ project is to identify new drug targets for HIV. read more

900,000 euros for new research on Lyme disease

1 February 2017 3 ZonMw grants for Lyme disease read more